Exscientia Stock (NASDAQ:EXAI)
Previous Close
$4.90
52W Range
$3.80 - $7.91
50D Avg
$5.06
200D Avg
$5.33
Market Cap
$636.36M
Avg Vol (3M)
$664.43K
Beta
0.84
Div Yield
-
EXAI Company Profile
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.
EXAI Performance
Revenue Breakdown
Revenue Breakdown by Product/Service
| Product/Service | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| Licensing Fees - Opt-in Payments and Milestones Achieved | - | - | £18.58M |
| Service Fees | £104.00K | - | - |
| Licensing Fees - Upfront Payments and Research Funding | £19.98M | £26.55M | £8.32M |
| Service fees | - | £670.00K | £452.00K |
Fiscal year ends in Dec 23 | Currency in GBP
Peer Comparison
| Ticker | Company |
|---|---|
| SANA | Sana Biotechnology, Inc. |
| KYMR | Kymera Therapeutics, Inc. |
| VECT | VectivBio Holding AG |
| RVMD | Revolution Medicines, Inc. Warrant |
| MREO | Mereo BioPharma Group plc |
| BPMC | Blueprint Medicines Corporation |
| PDSB | PDS Biotechnology Corporation |
| IPSC | Century Therapeutics, Inc. |
| ADAP | Adaptimmune Therapeutics plc |
| RLAY | Relay Therapeutics, Inc. |
| RXRX | Recursion Pharmaceuticals, Inc. |
| UBX | Unity Biotechnology, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| AVIR | Atea Pharmaceuticals, Inc. |
| PIRS | Pieris Pharmaceuticals, Inc. |
| LPTX | Leap Therapeutics, Inc. |
| LIFE | aTyr Pharma, Inc. |
| ZURA | Zura Bio Limited |
| ELEV | Elevation Oncology, Inc. |